ICU Resource Use in Critically III Patients following Chimeric Antigen Receptor T-Cell Therapy

Am J Respir Crit Care Med. 2020 Oct 15;202(8):1184-1187. doi: 10.1164/rccm.202002-0286LE.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cohort Studies
  • Critical Illness / mortality
  • Critical Illness / therapy*
  • Female
  • Humans
  • Immunotherapy, Adoptive / adverse effects*
  • Immunotherapy, Adoptive / methods*
  • Intensive Care Units / statistics & numerical data*
  • Length of Stay
  • Lymphoma, Non-Hodgkin / pathology*
  • Lymphoma, Non-Hodgkin / therapy*
  • Male
  • Middle Aged
  • Prognosis
  • Receptors, Chimeric Antigen / administration & dosage
  • Retrospective Studies
  • Risk Assessment
  • Survival Rate
  • Treatment Outcome

Substances

  • Receptors, Chimeric Antigen